Cell Genesys (CEGE) Slammed After Halting Trial Due To Deaths
Tweet
Share
E-mail
Shares of Cell Genesys, Inc. (Nasdaq: CEGE) are under heavy pressure this morning (-75%), following news the company terminated VITAL-2, the second of two Phase 3 clinical trials of GVAX immunotherapy for prostate cancer, which compares GVAX immunotherapy in combination with Taxotere to Taxotere plus prednisone in patients with advanced-stage prostate cancer.
Cell Genesys ended the trial as recommended by its Independent Data Monitoring Committee which, in a routine safety review meeting held this week, observed an imbalance in deaths between the two treatment arms of the study.
Cell Genesys ended the trial as recommended by its Independent Data Monitoring Committee which, in a routine safety review meeting held this week, observed an imbalance in deaths between the two treatment arms of the study.
You May Also Be Interested In
- FDA: issues early alert on Abiomed heart pump controller purge cassette issue
- Banks Moving Forward With Global Stablecoin Consortium - WSJ
- Meta reaches $16.68 billion settlement over social media harms to children
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
